Bio-Techne Corporation (TECH) Stock
TECH Key Statistics
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
CEO: Kim Kelderman. Company website
TECH — Frequently Asked Questions
What is the TECH stock price today?
Bio-Techne Corporation (TECH) trades at $72.37, down 0.06% on the day, as of Sep 20, 2026 14:59 UTC.
What is Bio-Techne Corporation's market cap?
Bio-Techne Corporation has a market capitalisation of $11.33B, calculated from the live TECH share price and shares outstanding.
What is the P/E ratio of TECH?
TECH trades at a trailing P/E of 62.39, from earnings per share of $1.16 over the last twelve months.
How much revenue does Bio-Techne Corporation make?
Bio-Techne Corporation generated revenue of $1.22B over the trailing twelve months, which puts the stock at 9.33 times sales.
Does TECH pay a dividend?
Yes. Bio-Techne Corporation pays a dividend yielding 0.46% on the current share price.
What is the 52-week range for TECH?
TECH has traded between $43.20 and $72.62 over the past 52 weeks, and the last price is 0.3% below that high.
Is Bio-Techne Corporation profitable?
Yes. Bio-Techne Corporation keeps 14.97% of revenue as net income over the trailing twelve months.
What is the analyst price target for TECH?
Wall Street analysts rate TECH Hold, with an average price target of $65.78, 9.1% below the current price.
What sector is Bio-Techne Corporation in?
Bio-Techne Corporation is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.
Who is the CEO of Bio-Techne Corporation?
Kim Kelderman is the chief executive of Bio-Techne Corporation, which employs 3,000 people.
Where can I track TECH in real time?
QFI Terminal shows TECH with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See TECH live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open TECH in Terminal See plans